- About us
- Clinical trials
- News & Publications
SOTIO’s lead candidate from its proprietary ADC platform is SOT102 (formerly SO-N102), targeting Claudin18.2 (CLDN18.2).
SOT102 has demonstrated potent anti-tumor efficacy in vitro and in vivo and, due to NBE’s proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform, has superior manufacturing properties including stability and aggregation propensity. Learn more HERE.